Stockscreener 앱 받기
159.99
1.90%
-3.10
시간 외 거래:
152.50
-7.49
-4.68%
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal - Zacks Investment Research
Why is Novartis stock sliding today? - Investing.com
Novartis shares fall after heart drug fails late-stage trial - in.investing.com
Novartis shares fall after heart drug fails late-stage trial By Investing.com - Investing.com Canada
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Novartis stock slips as Jefferies and UBS stay neutral after Hybrozyme deal - AD HOC NEWS
Novartis stock gains as remibrutinib data and Fabhalta growth offset cell therapy trial pause - AD HOC NEWS
Novartis Up 5.6% After MS Pill Gains $3 Billion Sales Potential - TechStock²
Novartis stock gains as remibrutinib MS data offsets CAR T trial pause - AD HOC NEWS
Why Is Novartis Stock Soaring Tuesday?Novartis (NYSE:NVS) - Benzinga
Novartis remibrutinib cuts MS relapse rates in Phase 3 - grafa.com
US markets today: Dow, S&P 500, Nasdaq futures indicate gap-down open; Novartis, Duolingo, energy stocks to watch - Upstox
Novartis shares rise after multiple sclerosis drug hits late-stage trial goals - Investing.com
Novartis stock steadies after pause of autoimmune cell therapy trials - AD HOC NEWS
Novartis stock trades mixed as investors weigh post-earnings outlook - AD HOC NEWS
Novartis stock trades below consensus target as post-earnings digestion continues - AD HOC NEWS
Novartis stock holds steady as investors digest latest 2026 earnings and guidance - AD HOC NEWS
Novartis stock holds steady as oncology and Alzheimer’s pipeline draws attention - AD HOC NEWS
Novartis AGADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Novartis stock edges lower as investors look past recent FDA win - AD HOC NEWS
Novartis stock trades steadily as Q2 2026 earnings growth supports outlook - AD HOC NEWS
Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors - ChartMill
Novartis stock extends its rally as investors weigh valuation and cardiovascular data plans - Ad-hoc-news.de
Novartis stock holds above $150 after orphan drug update - Ad-hoc-news.de
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Novartis stock holds above $150 as orphan drug milestone and earnings strength support valuation - Ad-hoc-news.de
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Novartis AG Sponsored ADR Revenue Breakdown – MUN:NOTA - TradingView
Novartis stock slips after UK patent win and strong Q2 2026 - Ad-hoc-news.de
Novartis stock slips from recent highs as investors digest latest quarter - Ad-hoc-news.de
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis (NYSE:NVS): A Top Dividend Stock with Strong Fundamentals and Sustainable Payouts - ChartMill
Weekly Recap: Novartis Q2 net sales up ~1–3% and Entresto 50% sales drop - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Revenue Breakdown – BCBA:NVSB - TradingView
Novartis AG Sponsored ADR Revenue Breakdown – SWB:NOTA - TradingView
Novartis stock trades steady as Q1 2026 revenue grows and Cosentyx expansion supports outlook - Ad-hoc-news.de
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline - Sahm
Novartis stock trades steady as Q2 2026 results highlight solid specialty medicines growth - Ad-hoc-news.de
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Novartis ADR earnings beat by $0.23, revenue topped estimates - Investing.com Canada
Novartis AG Stock (NVS) Moved Up by 3.42% on Jul 21: Key Drivers Unveiled - TradingKey
Novartis second quarter sales rise 3% to $14.4 billion - grafa.com
Earnings call transcript: Novartis tops Q2 2026 forecasts as shares rise - Investing.com
Novartis (NYSE: NVS) Q2 2026: key drugs surge while net debt jumps - Stock Titan
Novartis (NYSE:NVS) Faces A Defining Pipeline Test - Kalkine Media
NVS Stock Quote Price and Forecast - CNN
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Sahm
Novartis stock holds steady as pipeline and global reach underpin long-term growth - Ad-hoc-news.de
Stada Denied Speedy Trial In Novartis Heart Drug Patent Case - Law360
Novartis highlights drug pipeline strength as global healthcare demand grows - Ad-hoc-news.de
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Sahm
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - Barchart.com
Why Does Novartis AG-Sponsored ADR (NYSE:NVS) Track the NYSE Composite? - Kalkine Media
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout - ChartMill
1.26%
자본화:
|
볼륨(24시간):